Medical News

RSS

Making stem cells in the lab: a training program and a study

Young researchers will now be trained for the first time by the Australian Stem Cell Centre (ASCC) in scientific techniques of using and growing human induced pluripotent stem (iPS) cells in research. This training will be through StemCore iPS Cell Workshop, the ASCC's national facility for the provision of stem cells and advice.

5 May 2010

New breakthrough: Seaweed for treatment of swine flu

In a groundbreaking new discovery a Tasmanian company has used seaweed as treatment for swine flu. The lab trials have been going on for the past nine months using the undaria seaweed (better know as wakame seaweed) harvested from waters at Triabunna, of Tasmania's East Coast.

5 May 2010

Forbidding ambulance costs deter heart attack victims from calling ‘000’: National Heart Foundation

According to a new survey conducted by The National Heart Foundation, the forbidding ambulance costs are preventing timely calls to the emergency by at least one in 10 heart attack victims. The Foundation also released a discussion paper released during Heart Week urging free universal ambulance services in all states and territories. Dr Bill Coote in the paper entitled Universal Ambulance Cover has also said that this would prevent many heart attack deaths.

5 May 2010

School playground equipment impacts physical activity levels

Schools looking to make children more active simply need to provide more balls, skipping ropes, racquets and hoola hoops, a new study has shown.

5 May 2010

CPEX Pharmaceuticals reports record quarterly royalty revenues from Testim sales

CPEX Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010. For the quarter CPEX reported revenues of $5.3 million and a net loss of $940,000.

5 May 2010

TearScience completes $44.5 million Series C funding

TearScience, a privately-held medical device company, today announced the completion of $44.5 million of Series C funding from new investors Essex Woodlands Health Ventures, Investor Growth Capital and General Catalyst. The company's existing investors, De Novo Ventures, Spray Ventures and Quaker Bio Ventures completed the round. The funding will allow TearScience to commercialize its devices designed for use by eye care professionals to diagnose and treat the most common form of chronic dry eye disease.

5 May 2010

CAS Medical Systems reports revenues of $8.5 million for first-quarter 2010

CAS Medical Systems, Inc., today reported first quarter 2010 revenues of $8.5 million, an increase of $0.1 million, or 1%, compared to revenues of $8.4 million for the first quarter of 2009. The Company reported net income of $0.2 million, or $0.02 per basic and diluted common share, compared to a net loss of $0.9 million, or ($0.08) per basic and diluted common share, reported for the first quarter of the prior year.

5 May 2010

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the initiation of a Phase 2 clinical trial with ACE-031 in patients with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. ACE-031 is an investigational protein therapeutic that builds muscle and increases strength by inhibiting signaling of a cell surface receptor called the activin receptor type IIB (ActRIIB).

5 May 2010

BioTime first-quarter total revenue up 159% to $767,127

BioTime, Inc. today reported financial results for the first quarter ended March 31, 2010 and provided an update on recent corporate developments.

5 May 2010

Rockwell Medical first-quarter sales up 17.1%

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported first quarter 2010 results today.

5 May 2010

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Boehringer Ingelheim and Micromet, Inc. announced today that they have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.

5 May 2010

Spouses of dementia sufferers at higher risk of developing dementia

Older married adults whose spouse has dementia are at significantly higher risk for developing dementia themselves, compared to similar older married adults whose spouse never develops dementia. This is the key finding of a study published today in the Journal of the American Geriatrics Society.

5 May 2010

NxStage Medical first-quarter net revenue increases 20% to $40.4 million

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today reported financial results for the first quarter of 2010 ended March 31, 2010, with total revenue above the top end of its guidance range.

5 May 2010

Single night of partial sleep deprivation induces insulin resistance in healthy people

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), just one night of short sleep duration can induce insulin resistance, a component of type 2 diabetes.

5 May 2010

Triple-S Management first-quarter total consolidated operating revenues increase 9.8% to $519.1 million

Triple-S Management Corporation, the largest managed care company in Puerto Rico, today announced consolidated operating revenues of $519.1 million and operating income of $16.4 million for the three months ended March 31, 2010. Net income of $11.2 million, or $0.38 per diluted share, includes an after tax net gain of $0.4 million, or $0.01 per share, in net realized and unrealized gains on investments and derivatives.

5 May 2010

Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin

Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chronic Pseudomonas aeruginosa lung infection.

5 May 2010

New data on Surfaxin LS presented at 2010 PAS Annual Meeting

Discovery Laboratories, Inc., announced that new data regarding Surfaxin LS (its novel, lyophilized KL4 surfactant dosage form) were presented at the 2010 Pediatric Academic Societies Annual Meeting. The two studies presented demonstrate that Surfaxin LS improves lung function and oxygenation while attenuating lung inflammation in the preterm lamb model of respiratory distress syndrome.

5 May 2010

Viking Systems' first-quarter 2010 sales up 26%

Viking Systems, Inc. today announced financial results for its first quarter ended March 31, 2010. The Company reported a 26% increase in sales to $1,915,073 for the quarter ended March 31, 2010 and a net loss of $295,450 or ($0.01) per share.

5 May 2010

AMRI first-quarter total revenue down 9% to $49.3 million

AMRI today reported financial and operating results for the first quarter ended March 31, 2010.

5 May 2010

Cadence Pharmaceuticals resubmits OFIRMEV NDA

Cadence Pharmaceuticals, Inc. announced today that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational product candidate, OFIRMEV™ (acetaminophen) injection, for the treatment of pain and fever in adults and children.

5 May 2010